Company intelligence
DeciBio
Precision Medicine Strategy Consulting
About DeciBio
DeciBio Consulting is a boutique strategy consulting firm focusing on the life science industry. DeciBio's mission is to provide strategic insights that accelerate innovation in precision medicine. Headquartered in Los Angeles, CA, DeciBio serves clients and customers across the globe, ranging from incubator-stage startups to Fortune 500 life science corporations. DeciBio addresses business solutions that range from market landscape analyses to full commercial strategies, including organic and inorganic growth opportunities (commercial due diligences). DeciBio’s work is typically supported by a mix of primary and secondary research leveraging Dexter, its in-house expert network, and DeciBio Analytics’ proprietary data intelligence products. DeciBio’s Analytics division offers numerous data products to support strategic insights, including in clinical diagnostics (the DxBooks), oncology biomarkers, liquid biopsy, NGS, spatial biology, omics market segmentation (Market Reports), the entire life sciences industry (BioTrack), and more. Internal teams such as the Culture Committee, Women* in Consulting, and Queers in Consulting enrich the employee experience. DeciBio’s Social Impact board and the DeciBio Impact Lab work collaboratively across divisions and externally to uproot discrimination and increase access to precision medicine. DeciBio Consulting, LLC recently launched DeciBio Ventures. This venture capital and creation firm invests in and supports ground-breaking companies in the precision medicine space.
Verified activity
Signals from DeciBio
15 published signals
Customers & Market
DeciBio notes that at UGM 2026, Epic laid out a broad push to build AI into the EHR itself with Ergo arriving in November.
Reported by DeciBio
Customers & Market
DeciBio notes that R1 RCM agreed to acquire Humata Health, folding touchless prior authorization into its Phare OS platform.
Reported by DeciBio
Research & Knowledge
DeciBio asked its panel about the downside of consolidation in digital pathology.
Reported by DeciBio
Customers & Market
DeciBio notes that Epicrispr Biotechnologies closed an oversubscribed $90M Series C to advance EPI-321 toward pivotal studies in FSHD.
Reported by DeciBio
Customers & Market
DeciBio notes that CARsgen Therapeutics received NMPA IND clearances for two allogeneic candidates on its THANK-u Plus platform, marking its push into off-the-shelf CAR-T.
Reported by DeciBio
Customers & Market
DeciBio notes that Zelluna cleared the first safety review in ZIMA-101, the first clinical test of a TCR-NK therapy, with no dose-limiting toxicities observed.
Reported by DeciBio
Customers & Market
DeciBio notes that The FDA granted accelerated approval to Ultragenyx's GENGLYCOS for glycogen storage disease type Ia, the first approved therapy for the condition.
Reported by DeciBio
Customers & Market
DeciBio notes that Silence Therapeutics plc's divesiran hit its Phase 2 SANRECO primary endpoint in polycythemia vera.
Reported by DeciBio
Customers & Market
DeciBio notes that REGENXBIO disclosed that the FDA placed RGX-121 for Hunter syndrome on clinical hold following asymptomatic spinal MRI abnormalities in five previously treated participants, and no longer expects a near-term BLA resubmission.
Reported by DeciBio
Customers & Market
DeciBio notes that Opus Genetics completed enrollment in its registrational trial of OPGx-LCA5, and Taysha Gene Therapies named Catalent primary commercial manufacturer for TSHA-102 in Rett syndrome.
Reported by DeciBio
Customers & Market
DeciBio notes that Merck and Co Inc and Moderna's intismeran autogene plus Keytruda met both RFS and DMFS endpoints in the Phase 3 INTerpath-001 trial in resected Stage IIB–IV melanoma, a first in the adjuvant setting.
Reported by DeciBio
Customers & Market
DeciBio notes that Johnson & Johnson entered a collaboration with Sail Biomedicines to advance in vivo CAR-T for immune reset in immune-mediated diseases, paying $785M upfront and taking an option to acquire Sail for $2.58B.
Reported by DeciBio
Customers & Market
DeciBio notes that Full CARDIO-TTRansform data from Ionis Pharmaceuticals, Inc. and AstraZeneca, presented at ESC and published in NEJM, confirmed eplontersen missed its primary composite endpoint in ATTR-CM despite a 77% reduction in serum TTR.
Reported by DeciBio
Research & Knowledge
DeciBio sat down with Blanca Baez (Founder of DBounce) to pressure-test what the market sees against what her team found mapping ~350 players in the space and why it has barely improved in the last 20 years.
Reported by Luka Jelcic
Research & Knowledge
DeciBio conducted a survey of 100+ clinicians and pharma stakeholders in the neurodegenerative diseases market, assessing blood-based biomarker testing.
Reported by DeciBio